Colorectal Cancer Clinical Trial
Official title:
Effects of High Intra-abdominal Pressure on Tissue Diffusion and Pharmacokinetics of Cisplatin During HIPEC
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a
promising therapy for peritoneal carcinomatosis (PC) of various origins. Rather than the
pharmacokinetic advantage, the uptake of chemotherapy by tumor tissue has been proposed as
the best pharmacologic endpoint to assure the efficacy of HIPEC.
The primary endpoints of the present phase II randomized study are to test whether the
increased intra abdominal pressure (IAP) during HIPEC could:
- enhance the penetration of cisplatin into the residual neoplastic and normal tissues;
- elicit changes on pharmacokinetic advantage of cisplatin.
Secondary endpoints are to evaluate the:
- impact of high IAP on intraoperatory hemodynamic and respiratory parameters;
- impact on short-term surgical outcomes (in hospital stay, morbidity, mortality).
Patients affected by PC from colorectal cancer or pseudomyxoma peritonei, submitted to
complete cytoreduction (residual disease <2.5mm) would be eligible for the study. HIPEC will
be performed using closed abdomen technique and cisplatin + mitomycin-C. Patients will be
randomly assigned to HIPEC with low IAP (8-12 mmHg) or high IAP (18-22 mmHg). IAP will be
measured using bladder catheter. High IAP will be obtained increasing the volume of
perfusate.
Thirty-eight patients (19 in each study groups) will be enrolled in 30 months. The randomized
groups will be stratified according to tumor type.
Patients affected by peritoneal metastasis from colorectal cancer or pseudomyxoma peritonei,
submitted to complete cytoreduction (residual disease <2.5mm) would be eligible for the
study. Residual and resectable tumour nodules of 0.5 to 1.0 cm will be left behind after the
cytoreduction and they will be collected at the end of HIPEC for the purpose of this study.
HIPEC will be performed using closed abdomen technique and cisplatin (42mg/L of perfusate) +
mitomycin-C (3.3mg/m2/L of perfusate) for 60 minutes, at 42.5°C. Patients will be randomly
assigned to HIPEC with low IAP (8-12 mmHg) or high IAP (18-22 mmHg). IAP will be measured
using bladder catheter. Patients of high IAP group will be strictly monitored during the
perfusion regarding hemodynamic/respiratory parameters. During the HIPEC, perfusate and blood
samples will be collected every 10 minutes. Additional samples of arterial blood will be
collected at 70, 90,120,180 and 240 minutes. After the completion of HIPEC residual tumor
tissues, normal peritoneum and muscular fascia will be sampled for determination of cisplatin
concentration.
Blood samples will be immediately centrifuged to separate plasma. An aliquot of plasma will
be stored at -30°C for total platinum determination. Another aliquot will be ultrafiltered by
centrifugation through a membrane with a cut-off 5000 Da for ultrafilterable platinum
determination. The ultrafiltrate will be stored at -30°C until analysis.
Perfusate samples will follow the same procedure of blood samples. Tissues samples will be
stored at -80°C until analysis. Platinum determination will be performed using an Inductive
Coupled Plasma Mass Spectrometry (ICP-MS) system by Thermo Scientific after preparing
calibration curves with atomic platinum. Fluid samples simply dilute before ICP-MS
examination while tissues will be desiccated, digested with a mixture of nitric acid and
oxygen water, and evaporated to dryness prior to determination.
The investigators will compare the following outcomes between the study groups: tumor tissue
concentration of cisplatin; the area under the curve (AUC) ratio of perfusate UF
concentration of cisplatin times time to plasma UF concentration times time; in-hospital
stay; systemic toxicity (NCI-CTCAE.v3), morbidity, and mortality.
Thirty eight patients (19 in each group) would be needed to detect an increase cisplatin
concentration of 20 ng/mg of tumor tissue if patients are submitted to high-IAP during HIPEC,
assuming alfa=0.05 and power=0.90 and standard deviation of 15 ng. Accrual time will be 30
months. The randomized groups will be stratified according to tumor type.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |